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Summary Paraffin wax embedded formalin-fixed benign breast disease tissue taken from 17 patients (15 with
microcystic disease and 2 with fibroadenoma) was studied for the presence of tissue bound prolactin using a
rabbit antiserum against human prolactin applied in conjunction with a highly sensitive modified version of
the dinitrophenyl (DNP)-hapten sandwich staining (DHSS) procedure. Sections taken from 14 of the 15 cases
showing apocrine cystic changes exhibited strong prolactin staining restricted to the cytoplasm of metaplastic
apocrine cells lining the cysts. Normal lobules and ducts and blunt duct proliferations were all negativc. as
were also the two cases of fibroadenoma. In contrast 6 out of 8 cases of breast cancer examined showed
heterogenously distributed cytoplasmic staining in the cancer cells.
Maximal prolactin staining in the apocrine cells was observed at antiserum dilutions as high as 1:60.000.
This compared favourably with a 1:120,000 dilution that gave maximal levels of staining in the
prolactotrophs present in serial sections taken from formalin fixed paraffin wax embedded post mortem
human anterior pituitaries. In both types of tissues the specific staining was abolished by pre-absorption of
the antiserum with human prolactin (10pgml-1). No staining was observed when the anti-prolactin serum
was either omitted or substituted with DNP-labelled normal rabbit serum.
Apocrine metaplasia in cystic disease of the breast has recently been found to be associated with an
increased breast cancer risk. The strong and selective presence of immunohistochemically demonstrable
prolactin in the metaplastic cells may be of significance in view of the hormone's known growth stimulating
effect on the breast epithelium.
For a long time apocrine metaplasia (or pink cell change),
associated with cystic breast epithelium, has been regarded
as having little or no significance in relation to malignant
breast disease. However, recent reports from 4 independent
groups suggest that apocrine cell metaplasia, in particular
papillary apocrine change, may represent a minor but
pathogenetically important marker of breast cancer risk
(Page et al., 1978; Roberts et al., 1984; Dixon et al., 1985;
Page & Dupont 1986; Haagensen 1986).
In normal breast tissue apocrine change is associated with
prolactin (PRL) directed milk production (Shiu & Friesen,
1980). In patients with cyclical mastalgia and nodularity a
consistent elevated pituitary PRL secretory activity in
response to domperidone and TRH provocation tests has
been found (Kumar et al., 1984), suggestive of a functional
role of PRL in the induction of painful nodularity.
Furthermore, in benign breast disease (BBD) subjected to
biopsy, nodularity is often associated with microcystic
change that shows variable degrees of apocrine metaplastic
change in the epithelium lining the cysts (Craigmyle, 1984).
The highly focal nature of such a change has prevented
direct biochemical examination of a possible role played by
PRL. On the other hand, successful identification of PRL
presence has recently been reported in breast tissue sections
using an immunohistochemical approach (Dhadly & Walker
1983; Purnell et al., 1982; Marchetti et al., 1984). This study
was designed to examine whether or not apocrine
metaplastic change in BBD is associated with the presence of
immunohistochemically detectable PRL.
Materials and methods
Formalin fixed paraffin wax embedded tissues from 17
selected cases of benign breast disease biopsy were examined.
There were 15 cases with microcystic disease and 2 fibro-
adenomas. Cysts lined by flattened epithelium and varying
heights of apocrine metaplastic cells were present in all the
15 cases chosen. Several of the cysts had both types of lining
in the same cyst. Although none of the first set of sections
showed papillary apocrine change or atypical hyperplasia,
examination of a further series of sections (up to 4 in each
case) taken from separate blocks showed papillary apocrine
change to be present in all the 15 cases with microcystic
disease, as defined by the criterion of Page et al. (1978). In 2
cases there was evidence of epitheliosis without atypia, 2 had
sclerosing adenosis and 8 showed typical blunt duct
proliferation. In addition sections from 8 breast carcinoma
cases were examined and at least two of these had apocrine
change in the background breast tissue. All the cancers were
invasive ductal carcinomas. From 8 to 10 semi-adjacent 5 pm
sections were cut from the paraffin wax blocks and mounted
on chrome gel coated glass slides. A section from a formalin
fixed paraffin wax embedded post-mortem anterior pituitary
was included in each batch as a positive control. Similarly,
lymph node and thyroid sections were included as negative
controls. The biopsy specimens were from 2 to 8 years old.
Immunoperoxidase labelling
The dinitrophenyl (DNP)-hapten sandwich staining (DHSS)
procedure (Jasani et al., 1981) in its modified form (Jasani &
Williams, 1985; Jasani et al., 1985) was used throughout for
immunoperoxidase labelling of the tissue sections.
Rabbit anti-human prolactin (Rb aPRL; NIAMDD No.
AFP Cl 1580) was obtained as a gift from the National
Institute of Arthritis, Metabolic and Digestive Disease
(Bethesda, Maryland, USA). This was non-deleteriously
DNP-labelled as described previously (Hewlins et al., 1984).
The resulting DNP a-PRL was tested over a dilution range
of 1:15,000 to 1:480,000 using an incubation period of 16h
at 4°C. The secondary detection reagents, IgM anti-DNP
monoclonal bridge antibody, DNP-labelled peroxidase
conjugate and DNP-glucose oxidase, were each applied for
45 min with washing in phosphate-buffered saline (PBS) in
between each step. The colour reaction was developed using
diaminobenzidine and the nascent hydrogen peroxide
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generated by glucose (Jasani & Williams, 1985; Jasani et al.,
1985). All the sections were finally counterstained with
Mayer's haemalum, cleared through xylene and mounted
permanently in Terpene.
Control studies included omission of DNP-aPRL and
substitution with the appropriate dilution of dinitro-
phenylated normal rabbit serum (DNP-NRS) and incubation
with DNP-aPRL preabsorbed with highly pure human PRL
10 ugml-1 (NIAMDD, AFP 2284C2). Studies were also
performed to examine the effect of exposing sections to the
highly pure human PRL prior to treatment with DNP-aPRL
antibody.
All the slides were examined and assessed for the immuno
peroxidase staining independently by two observers (SK and
BJ).
Results
Of the 17 BBD tissue blocks studied, one specimen with only
mild cystic changes and two fibroadenomas were negative
for specific staining over the DNP-aPRL concentration
range examined. The remaining 14 showed the following
typical staining characteristics agreed upon by both the
observers. Papillary apocrine change was consistently
associated with the strongest intensity of staining (Figure
la). Tall apocrine metaplastic cells lining the cyst walls were
also consistently stained well above the background level and
the reaction was predominantly localised within the cell
cytoplasm. Flattened cyst epithelium showed specific staining
in only 2 specimens, the staining being considerably weaker
than that associated with the taller cells. Blunt ducts lined by
the normal double layer of cells did not stain. Other
metaplastic areas, epitheliosis (in 2 specimens) and adenosis
(in 2 specimens) stained rather weakly and heterogenously.
Morphologically normal lobules and ducts gave no staining.
Background staining of the breast parenchyma and collagen
was not prominent in the majority of the cases though weak
non-specific staining at the periphery of the sections was a
commonly observed phenomenon and was ruled out as an
edge or a drying artefact.
The optimal staining reaction was obtained at the dilution
of 1:60,000 of DNP-aPRL diluted in BSA. A similar level of
staining reaction in the anterior pituitary sections was
observed consistently at 1: 120,000 dilution. Sections of
lymph node and thyroid tissue with oxyphil change did not
immunostain at any of the dilutions tested. Prior incubation
of the sections with human PRL resulted in a markedly
enhanced staining level (Figure lb) similar in intensity to
that seen with a higher concentration (i.e. 1:15,000 dilution)
of DNP-aPRL serum but without a parallel increase in the
background level, thus indicative of a genuine and specific
enhancement. In contrast, omission of DNP-aPRL or its
substitution with DNP-NRS abolished specific staining as
did prior absorption of the DNP-aPRL with the highly pure
human PRL preparation (Figure lc). All the control
experiments were performed at least twice with 6 sections in
each batch.
Of the 8 breast carcinoma cases positive reaction was seen
in individual sections examined from 6 cases. Two of the
positive cases had, in addition, strongly PRL positive
apocrine change in the background breast tissue. The
immunostained cells were found generally intermixed with
variable numbers of unstained cancer cells. However, normal
epithelial cells even within the tumorous areas were
consistently negative. The specific staining was again mainly
of the cytoplasmic type although in 2 specimens there was
some irregular staining of the cell periphery as well as of
some nuclei.
Discussion
The results of this study indicate a fairly consistent presence
of immunohistochemically demonstratable PRL in histo-
Figure 1 Immunohistochemical demonstration of prolactin in
apocrine metaplastic epithelium: (a) immunoperoxidase staining
obtained using DNP-labelled rabbit anti-PRL serum (1:60,000,
16h, 4°C) applied in conjunction with the modified DHSS
procedure. Note the restriction of the staining to the exuberantly
metaplastic cyst-lining cells; (b) marked and selective
enhancement of the staining resulting from prior incubation of a
serial adjacent section with highly pure human prolactin
(10igmg-1, 1 h, 20°C); (c) abolition of the staining by pre-
absorption of the antiserum with the highly pure human
prolactin (I0Mgml 1, 30min, 37°C).
logically definable apocrine metaplastic cells, particularly the
papillary apocrine change variety, found within benign
breast disease. The PRL immunostaining was also found
with a high regularity in breast cancer specimens.
We have employed a highly sensitive immunohistochemical
method for the examination of PRL immuno reactivity in
formalin fixed and paraffin wax embedded breast sections.
Our success with formalin fixed paraffin wax embedded
tissue is, however, contrary to a previous report where the
use of fresh frozen tissue was found essential (Dhadly &
Walker, 1983). Nevertheless, Purnell et al. (1982) were able
to demonstrate cytoplasmic PRL binding in paraffin wax
embedded tissue but using an antiserum against bovine PRL.
Similar results have been also reported by Marchetti et al.
(1984) using both fresh and formalin fixed tissue. Staining of
the epithelial cells of ducts and lobules seen in normal and
hyperplastic benign breast tissue was described in these
studies. These authors have not, however, specifically
commented on any staining reaction associated with
apocrine epithelium (i.e. if present) in the tissues examined
by them. On the other hand, in our study the normal acinar
or ductular epithelium did not stain significantly with aPRL.
The immunohistochemically detectable presence of PRL
within the apocrine metaplastic cells a priori may imply
either a target status, transcellular transport mechanism, de
novo synthesis or degradation function for these cells with
regard to this hormone. The fact that addition of exogenous
PRL onto the sections led to considerable selective
enhancement of the anti-PRL mediated staining of the
apocrine metaplastic cells indicates that the cells are involved
in the production of PRL specific binding sites, probably
PRL receptors. If so, this could suggest a target function on
the part of metaplastic cells for PRL. In situ hybridisation
studies with a gene probe directed against the messenger
RNA of PRL receptor may be one way of directly
confirming this possibility on the available amounts of tissue
material.
The breast is under cyclical control of various hormones
throughout the reproductive life of a woman, yet consistent
changes in basal plasma hormone levels have not been
detected in breast disease. Recently women with cyclical
mastalgia and nodularity have been shown to exhibit an
increased PRL response to TRH or domperidone
provocation (Kumar et al., 1984). Prolactin is known to
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Friesen, 1980). PRL regulates water and electrolyte balance,
milk protein synthesis, uridine conversion and incorporation
into DNA, and breast fatty acid synthetase activity. An
increased synthesis of oestrogen receptor has also been
reported. The role of PRL in the overall causation of
benign breast pathology is uncertain. However, treatment
with bromocriptine, a PRL lowering dopaminergic agent was
successful in alleviating painful nodularity and cyclical
mastalgia (Mansel et al., 1978). The determination and the
level of specific PRL binding sites in normal and abnormal
breast tissues may therefore be useful in better understanding
of the patho-physiology of benign breast disease. The weak
and rather heterogenously distributed PRL staining in the
other types of BBD lesions, e.g. epitheliosis and sclerosing
adenosis, is difficult to rationalise because of the very few
instances in which it was observed.
The significance of PRL presence in apocrine metaplastic
cells of BBD in relation to the possible association ofapocrine
metaplasia with breast cancer development is discussed
briefly below.
Apocrine metaplasia or pink cell change, characterized by
high cylindrical cells with granular eosinophlic cytoplasm
projecting as 'snouts' into the lumen of the ducts and cysts,
has long been regarded of no significance in cancer risk.
Similarly breast carcinoma originating from apocrine
metaplasia has long been considered to be a relatively rare
event (Foote & Stewart, 1945). However, Haagensen has
recently reported a very much higher incidence of apocrine
type of breast carcinoma. For example, 60% apocrine
differentiation of cancer cells was seen in a series where
cancer developed in patients with concomitant gross cystic
disease and 26% carcinomas with apocrine features were
seen in an unselected series of 124 cases (Haagensen, 1986).
Increased cancer risk of 2 to 10 times has been reported
recently in 2 other independent studies involving long term
follow-ups of patients whose initial biopsy had shown
apocrine metaplasia (Page et al., 1978; Roberts et al., 1984).
However, Dupont & Page (1985) in an updated study have
regarded apocrine metaplasia as a non-proliferative benign
breast lesion without a significant risk for breast cancer.
Nevertheless, the frequency of apocrine differentiation in
breast carcinomas assessed on purely morphological grounds
is controversial (Craigmyle, 1984). The need to have more
objective criteria of defining apocrine cell types under the
light microscope has been emphasised in a recent article
(Eusebi et al., 1984). The availability of an antibody specific
for apocrine carcinoma reported in the latter article is likely
to help to determine the true level of association between
apocrine metaplasia and breast cancer in general.
The high proportion of the breast cancer tissue staining
for PRL observed in this study is in keeping with the
findings of previous workers (Dhadly & Walker, 1983;
Marchetti et al., 1984; Purnell et al., 1982). Also it is
possible that the PRL positive breast cancer cells seen in the
present study may represent cells depicting apocrine type
breast carcinoma differentiation. This possibility needs to be
examined by independent markers such as the antibody to
GCDFP-15, a specific marker for apocrine metaplasia
described by Haagensen and co-workers (Haagensen, 1986;
Eusebi et al., 1984). However, it is of interest to note that at
least 2 out of 6 carcinoma cases positive for PRL staining
were recognised to have PRL positive apocrine change in the
background breast tissue despite being sampled on a limited
and a rather random basis. A systematic approach to
estimating the true incidence of PRL positive apocrine
change in the background breast tissue of breast cancer
patients is clearly called for in the future.
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